Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plixorafenib - Daiichi Sankyo Company

Next Previous
Drug Profile

Plixorafenib - Daiichi Sankyo Company

Alternative Names: FORE 8394; PLX-8394

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Daiichi Sankyo Company; Fore Biotherapeutics; Plexxikon
  • Class Antineoplastics; Cyclopropanes; Fluorobenzenes; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS cancer; Solid tumours
  • Discontinued Hairy cell leukaemia; Malignant melanoma

Most Recent Events

  • 12 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by FORE Biotherapeutics
  • 10 Apr 2024 Updated interim efficacy data from a phase I/IIa trial in Solid tumours released by FORE Biotherapeutics
  • 17 Nov 2023 Updated efficacy and adverse events data from a phase trial I/II trial in Solid tumour released by Fore Biotherapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top